Literature DB >> 19542802

Anticonvulsants for neuropathic pain: gaps in the evidence.

Felicity Goodyear-Smith1, Joan Halliwell.   

Abstract

OBJECTIVE: To summarize the available evidence on the use of anticonvulsant drugs for the treatment of various conditions of neuropathic pain.
METHODS: This is a systematic review on quantity and quality of evidence for using anticonvulsants in the management of neuropathic pain. Medical Subject Heading terms searched were "anticonvulsants" and "pain." Data sources used were the Cochrane Controlled Trials Register, Cochrane Database of Systematic Reviews, Medline 1966 to May 2006, Embase 1980 to May 2006, and CINAHL 1982 to May 2006. Additional studies were identified by hand searching the reference lists of retrieved papers and by autoalerts subsequent to May 2006. Randomized controlled trials, systematic reviews, and meta-analyses included. Non-English papers excluded. Evidence and evidence gaps with regard to specific conditions and drugs identified.
RESULTS: Concise summary of all existing evidence or lack thereof was produced. A succinct table is presented of the efficacy of specific drugs for specific conditions and the nature and quality of evidence. The paper outlines the incidence of specific neuropathic pain conditions within various population groups and assesses the quantity of available evidence in regard to the frequency that those conditions are likely to occur. DISCUSSION: Gaps in the evidence are striking. Recommendations directly supported by the evidence by drug and by condition are made.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542802     DOI: 10.1097/AJP.0b013e318197d4cc

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  7 in total

1.  Preclinical Comparison of Mechanistically Different Antiseizure, Antinociceptive, and/or Antidepressant Drugs in a Battery of Rodent Models of Nociceptive and Neuropathic Pain.

Authors:  Misty D Smith; Jose H Woodhead; Laura J Handy; Timothy H Pruess; Fabiola Vanegas; Erin Grussendorf; Joel Grussendorf; Karen White; Karolina K Bulaj; Reisa K Krumin; Megan Hunt; Karen S Wilcox
Journal:  Neurochem Res       Date:  2017-05-15       Impact factor: 3.996

2.  Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-11-04       Impact factor: 3.533

3.  Pharmacovigilance in hospice/palliative care: net effect of gabapentin for neuropathic pain.

Authors:  Christine Sanderson; Stephen J Quinn; Meera Agar; Richard Chye; Katherine Clark; Matthew Doogue; Belinda Fazekas; Jessica Lee; Melanie R Lovell; Debra Rowett; Odette Spruyt; David C Currow
Journal:  BMJ Support Palliat Care       Date:  2014-10-16       Impact factor: 3.568

4.  Management of chronic neuropathic pain: a protocol for a multiple treatment comparison meta-analysis of randomised controlled trials.

Authors:  Sohail M Mulla; D Norman Buckley; Dwight E Moulin; Rachel Couban; Zain Izhar; Arnav Agarwal; Akbar Panju; Li Wang; Sun Makosso Kallyth; Alparslan Turan; Victor M Montori; Daniel I Sessler; Lehana Thabane; Gordon H Guyatt; Jason W Busse
Journal:  BMJ Open       Date:  2014-11-20       Impact factor: 2.692

Review 5.  Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects.

Authors:  Brigitte A Brouwer; Bianca T A de Greef; Janneke G J Hoeijmakers; Margot Geerts; Maarten van Kleef; Ingemar S J Merkies; Catharina G Faber
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

Review 6.  Current Status of the New Antiepileptic Drugs in Chronic Pain.

Authors:  Harpreet S Sidhu; Akshay Sadhotra
Journal:  Front Pharmacol       Date:  2016-08-25       Impact factor: 5.810

Review 7.  Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain.

Authors:  Marta Vázquez; Natalia Guevara; Cecilia Maldonado; Paulo Cáceres Guido; Paula Schaiquevich
Journal:  Biomed Res Int       Date:  2020-08-13       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.